Drug/indication:Bydureon for diabetes
Approval decision date:Oct. 22, 2010
Recent stock performance: At just over $20 a share, Amylin is up 43% for the year.This is the second FDA review cycle for Bydureon, a once-weekly injectable drug for diabetes.
Vivus (VVUS - Get Report) Drug/indication: Qnexa for obesity Approval decision date: October 28, 2010 Recent stock performance: At $5.61, Vivus' value was cut in half by the negative FDA advisory panel vote. The odds in favor of Qnexa's approval took a big hit in July when an FDA advisory panel voted against the drug's approval due to a lack of long-term safety data. Vivus is expected to announce results from a two-year safety study of Qnexa in the third quarter.
Biodel (BIOD) Drug/indication: VIAject for diabetes Approval decision date: Oct. 29, 2010 Recent stock performance: Closed Friday at $3.88. The stock has traded as low as $3.22 and as high as $6.25 this year. VIAject is a fast-acting insulin analogue designed for absorption into the bloodstream faster than currently marketed rapid-acting insulins.